BDX Stock Forecast & Price Target

Becton Dickinson has demonstrated robust growth across its segments, with the Medical Surgical segment reporting sales of $888 million in FQ3'25, reflecting a year-over-year increase of 5.3%, driven by strong demand in Infusion Systems and Dispensing Solutions. Additionally, the company's MedTech business has been growing consistently at a rate exceeding 6% annually since the launch of its BD 2025 initiative, accompanied by improving margins. The BD Life Sciences unit also contributed positively, achieving sales of $629 million in FQ3'25, which represents a 4.8% year-over-year growth on an ex-foreign exchange basis, showcasing the resilience and capacity for expansion within this key segment.

Becton Dickinson has reaffirmed its organic revenue growth outlook at 3.0-3.5% year-over-year, a decrease from the previously projected range of 4.0-4.5% issued in late 2024, indicating a deterioration in growth expectations. In the third quarter of fiscal year 2025, the company reported sales of $1.25 billion, reflecting a 1.1% decline year-over-year (excluding foreign exchange), primarily driven by declines in its Biosciences and Diagnostic Solutions segments. Additionally, Becton Dickinson faces significant challenges, including volume-based procurement headwinds in China and reduced demand in the Bioscience sector due to government funding cuts, further compounding concerns about future revenue growth.